NASDAQ:RLYB Rallybio Q3 2024 Earnings Results & Report $16.28 -0.49 (-2.92%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$16.33 +0.05 (+0.31%) As of 10/16/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Rallybio beat analyst earnings expectations in its Q3 2024 results, released November 7, 2024. The company reported EPS of -$2.08 versus the -$2.88 consensus estimate, while revenue was $0.30 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 7, 2024TimeBefore Market OpensConference Call8:00 AM ET Rallybio EPS ResultsActual EPS-$2.08Consensus EPS -$2.88Beat/MissBeat by +$0.80One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersRallybio Revenue ResultsActual Revenue$0.30 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsRallybio's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Rallybio Q3 2024 Earnings FAQ Did Rallybio beat earnings estimates for Q3 2024? Rallybio (NASDAQ:RLYB) reported earnings of -$2.08 per share for Q3 2024, beating the consensus estimate of -$2.88. The report was announced on Thursday, November 7, 2024. What was Rallybio's revenue for Q3 2024? Rallybio reported revenue of $0.30 million for Q3 2024. When is Rallybio's next earnings date? Rallybio's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Rallybio on the company's earnings history page. Rallybio Earnings HeadlinesHead to Head Analysis: Alector (NASDAQ:ALEC) & Rallybio (NASDAQ:RLYB)October 12, 2026 | americanbankingnews.comRallybio CFO Transition Amid Pending Avenzo Therapeutics MergerSeptember 9, 2026 | tipranks.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBJune 2, 2026 | businesswire.comRLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?June 1, 2026 | finance.yahoo.comRLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its ShareholdersJune 1, 2026 | businesswire.comSee More Rallybio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rallybio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rallybio and other key companies, straight to your email. Email Address About RallybioRallybio (NASDAQ:RLYB) is a clinical-stage biotechnology company focused on developing medicines for rare diseases and conditions with significant unmet medical needs. The company’s research and development efforts are directed toward therapies that address serious disorders in areas such as maternal-fetal health, hematology and immunology. Rallybio’s lead program, RLYB212, is designed to prevent hemolytic disease of the fetus and newborn caused by maternal alloimmunization against the Kell antigen. The company has also developed investigational therapies that target the complement system, an immune pathway involved in a range of rare and severe diseases. Founded in 2018, Rallybio is headquartered in New Haven, Connecticut. Its programs are being developed through clinical research intended to support potential future treatments in the United States and other markets, subject to regulatory approval. The company’s management and development teams include biotechnology and pharmaceutical industry professionals with experience in drug discovery, clinical development and commercialization.View Rallybio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
